Latest Isis Stories

Roche and Isis Pharmaceuticals form alliance for Huntington's disease

2013-04-08 08:31:17

BASEL, Switzerland, and CARLSBAD, Calif., April 8, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Isis Pharmaceuticals, Inc (NASDAQ: ISIS) today announced that they have formed an alliance to develop treatments for Huntington's disease (HD) based on Isis' antisense oligonucleotide (ASO) technology. This alliance combines Isis' antisense expertise with Roche's scientific expertise in developing neurodegenerative therapeutics. In addition, Isis and Roche will be...

Sofia University Professor Lisa Herman to Present “Between Hope and Despair: Co-Creating with Disturbing Images” at ISIS Canada

2013-04-03 23:02:26

The event will be held on Friday, April 5, 2013, from 7:00 – 9:00 PM at ISIS Canada headquarters in Toronto. Palo Alto, CA (PRWEB) April 03, 2013 Sofia University (formerly Institute of Transpersonal Psychology) professor Lisa Herman will conduct a lecture and presentation titled, “Between Hope and Despair: Co-Creating with Disturbing Images,” at the International School of Interdisciplinary Studies in Canada (ISIS Canada). The event will be held on Friday, April 5, 2013, from 7:00...

Isis Initiates Phase 1 Study of ISIS-APOA Rx to Treat Atherosclerosis

2013-04-03 08:27:25

CARLSBAD, Calif., April 3, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-APOA(Rx), an antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis. Apolipoprotein(a) contributes to the formation of plaque in arteries through its attachment to an LDL-C particle in a complex termed lipoprotein(a), or Lp(a). High levels of Lp(a) are associated with an increased risk of...

Isis Provides Update on CHMP Opinion on KYNAMRO(TM) (mipomersen)

2013-03-22 16:23:38

CARLSBAD, Calif., March 22, 2013 /PRNewswire/ -- Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that following Genzyme's request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) confirmed its previous position and has maintained a negative opinion regarding the marketing authorization application (MAA) for KYNAMRO(TM) (mipomersen) as a treatment for patients with Homozygous Familial Hypercholesterolaemia...

Data From ISIS-SMN Rx Phase 1 Study in Children With Spinal Muscular Atrophy Presented at the American Academy of Neurology Meeting

2013-03-20 20:22:52

Isis to host an investor event and live webcast at 7:30 am PT on Thursday, March 21 in San Diego CARLSBAD, Calif., March 20, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that data from the Phase 1 study of ISIS-SMN(Rx) in children with spinal muscular atrophy (SMA) were presented today at the 65(th) American Academy of Neurology (AAN) Annual Meeting by Dr. Claudia Chiriboga, from Columbia University Medical Center. In the presentation, Dr. Chiriboga...

Isis Solutions and Results Awarded Client Status of UCF Business Incubation Program

2013-03-18 12:25:38

Woman-Owned Florida Business Helps Clients Improve Organizational Performance ORLANDO, Fla., March 18, 2013 /PRNewswire/ -- Isis Solutions and Results, LLC (ISR), a Florida-based business that provides clients with professional consulting, writing and training solutions to improve organizational performance, has recently been selected to become an official client of the University of Central Florida Business Incubation Program (UCFBIP) at the Central Florida Research Park. (Logo:...

Isis Pharmaceuticals to Present at the 25th Annual ROTH Conference

2013-03-15 08:26:19

CARLSBAD, Calif., March 15, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 25(th) Annual ROTH Conference on Tuesday, March 19, 2013 at 8:00 a.m. PT in Laguna Niguel, CA. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be available on the Isis Web site...

Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-SMN Rx Data Presented at 2013 AAN Annual Meeting

2013-03-14 12:28:26

- Event and webcast scheduled on Thursday, March 21 at 7:30 a.m. Pacific Time CARLSBAD, Calif., March 14, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host an investor event and a live webcast on Thursday, March 21, 2013 at 7:30 a.m. Pacific Time to discuss the ISIS-SMN(Rx) Phase 1 data presented at the 2013 American Academy of Neurology Annual Meeting. Interested parties may register to attend the event in San Diego, CA, or access the...

Isis Pharmaceuticals Reports Clinical Data Showing Blunting of Severe Increases in CRP Following Endotoxin Challenge With ISIS-CRP Rx

2013-03-13 08:33:33

Up to 63% Reduction in CRP Response with ISIS-CRP Rx Treatment CARLSBAD, Calif., March 13, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that ISIS-CRP(Rx) selectively reduced severe elevations in C-reactive protein (CRP) in humans. Data from a Phase 1 clinical study showed that ISIS-CRP(Rx) produced statistically significant, dose-dependent reductions in CRP response following an endotoxin challenge, which produces immune responses similar to those...

Pipeline Initiatives, Partnerships to Drive Growth - Research Report on Pfizer, Theravance, ISIS Pharmaceuticals, Infinity Pharmaceuticals and Ironwood

2013-03-07 08:29:37

NEW YORK, March 7, 2013 /PRNewswire/ -- Today, Investors Alliance announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Theravance Inc (NASDAQ: THRX), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), Infinity Pharmaceuticals Inc. (NASDAQ: INFI) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Pfizer Inc. Research...